A single inhaled, disease-modifying PAH bet with a February 2026 binary catalyst—de-risked by Chiesi economics but still exposed to trial failure, competitive benchmarks, and future dilution.
Overview
Gossamer Bio (GOSS) is a San Diego-based, clinical-stage biopharmaceutical company focused on severe pulmonary and immunologic diseases, with enterprise value overwhelmingly driven by a single lead program: seralutinib (GB002), an investigational inhaled, dry-powder kinase inhibitor intended to be disease-modifying in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is pre-commercial and generates no product sales revenue; instead, reported revenue is derived from a global collaboration and licensing partnership with Chiesi (upfront/license consideration, milestones, and development cost reimbursements). In Q3 2025, Gossamer recognized $13.3M of collaboration revenue (including $9.2M cost reimbursement), while historical periods were skewed by one-time license recognition (e.g., $88.8M in Q2 2024). The clinical and equity inflection point is the fully enrolled, registrational Phase 3 PROSERA trial in PAH (390 patients; WHO FC II/III; on background therapy), with topline data expected in Feb 2026 and a primary endpoint of placebo-adjusted change in six-minute walk distance (6MWD) at week 24. PAH is a large and growing orphan market (roughly ~$8B+ in 2024–2025, with mid-single-digit CAGR projecting to the low-to-mid teens billions over the next decade), and North America is the largest revenue region due to infrastructure and reimbursement. Gossamer’s strategic narrative is that seralutinib may address underlying remodeling biology (proliferation/inflammation/fibrosis) rather than just vasodilation, potentially positioning it as an important add-on therapy in modern combination regimens. The investment profile is therefore highly asymmetric: a positive PROSERA readout could unlock a multi-billion-dollar franchise supported by Chiesi’s global commercialization capabilities, while a failure would likely trigger severe value impairment typical of single-asset biotech.